MedTrace Logo

Shared Decision-Making: AFib 2gether Mobile App

NCT04118270 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-05-02

Study results available
· View outcomes & findings →

Summary

Shared Decision-Making: AFib 2gether™ is a research study that focuses on a mobile application developed by Pfizer, Inc with consultation from Dr McManus' called AFib 2gether™. Through this app, patients can determine their risk of stroke due to atrial fibrillation and prioritize questions and concerns for discussion with their cardiology provider.

Conditions

  • Atrial Fibrillation New Onset

Interventions

DEVICE

Afib 2gether TM Mobile Application

The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Massachusetts, Worcester

    lead OTHER

Principal Investigators

  • Alok Kapoor, MD · UMass Medical School

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2020-06-26
Completion
2020-06-26
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04118270 on ClinicalTrials.gov